Rachel H Giles

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. ncbi Tumor suppressors APC and VHL: gatekeepers of the intestine and kidney
    Rachel H Giles
    Department Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Prog Mol Subcell Biol 40:151-81. 2005
  2. ncbi Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands
    Eur J Hum Genet 16:73-8. 2008
  3. ncbi Caught up in a Wnt storm: Wnt signaling in cancer
    Rachel H Giles
    Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands
    Biochim Biophys Acta 1653:1-24. 2003
  4. ncbi von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish
    Ellen van Rooijen
    Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Utrecht, The Netherlands
    Dis Model Mech 3:343-53. 2010
  5. ncbi Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2
    Dorus A Mans
    Laboratory of Experimental Oncology, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Cell Res 314:1229-36. 2008
  6. ncbi Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia
    Ellen van Rooijen
    Department of Medical Oncology, University Medical Center, Utrecht, The Netherlands
    Blood 113:6449-60. 2009
  7. ncbi The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, rm F02 126, 3584 CX Utrecht, The Netherlands
    FEBS Lett 581:4571-6. 2007
  8. ncbi Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients
    Jeanine M Roodhart
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neoplasia 12:87-94. 2010
  9. ncbi Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Biol Chem 280:22205-11. 2005
  10. ncbi Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
    Niven Mehra
    Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Clin Cancer Res 13:421-6. 2007

Collaborators

  • Emile E Voest
  • Rob B van der Luijt
  • Hans Clevers
  • Branko Braam
  • Frank C P Holstege
  • Laurien H Ulfman
  • Richard P Hill
  • Michael Ohh
  • Martijn P Lolkema
  • Ellen van Rooijen
  • Dorus A Mans
  • Niven Mehra
  • Moniek van Beest
  • Stefan Schulte-Merker
  • Morgan Nordstrom-O'Brien
  • Jeanine M Roodhart
  • Ive Logister
  • Fredericus J van Eeden
  • Jeroen Korving
  • Astrid E Greijer
  • Nancy van Daal
  • Maarten Penning
  • Jolanda Maas
  • Cristel M Snijckers
  • Hans A R Bluyssen
  • Ans M van den Ouweland
  • Jeroen Bussmann
  • Arnold Baars
  • Marlies H Langenberg
  • Aram van Brussel
  • Joost S Vermaat
  • Danielle F Majoor-Krakauer
  • Els O Witteveen
  • Thorsten Schwerte
  • Victor W M van Hinsbergh
  • Gerrit A Meijer
  • Pien M Delis-van Diemen
  • Laura G Daenen
  • Remond J A Fijneman
  • Carina van Rooijen
  • Stefano Volpi
  • Freek J van Eeden
  • Mascha van Noort
  • Laurens V Beerepoot
  • Carla H van Gils
  • Michelle L Gervais
  • Martijn F B G Gebbink
  • Maartje Los
  • Anita S Jorna
  • Martijn P J K Lolkema
  • Michelle Boone
  • Cristel M J T Snijckers

Detail Information

Publications17

  1. ncbi Tumor suppressors APC and VHL: gatekeepers of the intestine and kidney
    Rachel H Giles
    Department Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Prog Mol Subcell Biol 40:151-81. 2005
  2. ncbi Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands
    Eur J Hum Genet 16:73-8. 2008
    ..Furthermore, reduction of cellular levels of VHL in this cell system was associated with fewer ciliated cells, suggesting a role for VHL in ciliary maintenance...
  3. ncbi Caught up in a Wnt storm: Wnt signaling in cancer
    Rachel H Giles
    Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands
    Biochim Biophys Acta 1653:1-24. 2003
    ....
  4. ncbi von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish
    Ellen van Rooijen
    Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Utrecht, The Netherlands
    Dis Model Mech 3:343-53. 2010
    ..Importantly, they will allow for a cost-effective, non-invasive and efficient way to screen for novel pharmacological agents and combinatorial treatments...
  5. ncbi Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2
    Dorus A Mans
    Laboratory of Experimental Oncology, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Cell Res 314:1229-36. 2008
    ..From these data we suggest that mobility of a subcellular pool of pVHL is regulated by the ATP-dependent kinesin-2 motor. Kinesin-2 driven mobility of cytoplasmic pVHL might enable pVHL to function as a tumour suppressor...
  6. ncbi Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia
    Ellen van Rooijen
    Department of Medical Oncology, University Medical Center, Utrecht, The Netherlands
    Blood 113:6449-60. 2009
    ..They will contribute to our understanding of hypoxic signaling, hematopoiesis, and VHL-associated disease progression...
  7. ncbi The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, rm F02 126, 3584 CX Utrecht, The Netherlands
    FEBS Lett 581:4571-6. 2007
    ..The interaction with kinesin-2 facilitates pVHL binding to microtubules. These data suggest that microtubule-dependent functions of pVHL are influenced by kinesin-2...
  8. ncbi Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients
    Jeanine M Roodhart
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neoplasia 12:87-94. 2010
    ..The correlation with a clinical response and survival provides further support for the biologic relevance of these cells in patients' prognosis and stresses their possible use as a therapeutic target...
  9. ncbi Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Biol Chem 280:22205-11. 2005
    ..We propose that phosphorylation of the acidic domain plays a role in the regulation of proper fibronectin matrix deposition and that this may be relevant for the development of VHL-associated malignancies...
  10. ncbi Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
    Niven Mehra
    Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Clin Cancer Res 13:421-6. 2007
    ..We assessed whether we could distinguish poor from good prognosis patients at presentation in our clinic by means of quantifying circulating cell-free mitochondrial and genomic nucleic acids in plasma...
  11. ncbi Genetic analysis of von Hippel-Lindau disease
    Morgan Nordstrom-O'Brien
    Department of Medical Oncology, University Medical Center Utrecht, Universiteitsweg 100, Utrecht, The Netherlands
    Hum Mutat 31:521-37. 2010
    ..This easy-to-use compilation of VHL mutations is intended to facilitate research and function as a necessary adjunct for physicians when providing patient information...
  12. ncbi All along the watchtower: is the cilium a tumor suppressor organelle?
    Dorus A Mans
    Department of Medical Oncology, University Medical Center Utrecht, The Netherlands
    Biochim Biophys Acta 1786:114-25. 2008
    ..Furthermore, we predict that we are just now seeing the tip of the iceberg, and that the list of cancers associated with altered ciliary signalling will grow exponentially in the next few years...
  13. ncbi The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Cell Res 301:139-46. 2004
    ..Here we propose a complementary method to directly measure VHL-induced subcellular changes in microtubule dynamics, which may serve as a tool to study the effect of MT binding proteins such as VHL...
  14. ncbi LRRC50, a conserved ciliary protein implicated in polycystic kidney disease
    Ellen van Rooijen
    Hubrecht Institute, Developmental Biology and Stem Cell Research, University Medical Center Utrecht, Utrecht, Netherlands
    J Am Soc Nephrol 19:1128-38. 2008
    ....
  15. ncbi Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases
    Niven Mehra
    Department of Medical Oncology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Cancer Res 12:4859-66. 2006
    ....
  16. ncbi Fibronectin is a hypoxia-independent target of the tumor suppressor VHL
    Hans A R Bluyssen
    Department of Medical Oncology, University Medical Center Utrecht, P.O. Box 85500, 3500 GA, Utrecht, The Netherlands
    FEBS Lett 556:137-42. 2004
    ..Thus regulation of fibronectin deposition by VHL occurs at the transcriptional level, irrespective of oxygen levels...
  17. ncbi Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum
    Astrid E Greijer
    Department of Pathology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Virchows Arch 452:535-44. 2008
    ....